Log in

Relevant bibliographies by topics / Iron in chronic hepatitis C

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Iron in chronic hepatitis C'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Iron in chronic hepatitis C.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Iron in chronic hepatitis C"

1

Hayashi, Hisao, and Motoyoshi Yano. "Iron Cytotoxicity in Chronic Hepatitis C." JOURNAL OF HEALTH SCIENCE 48, no. 3 (2002): 227–31. http://dx.doi.org/10.1248/jhs.48.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Corengia, Chiara, Stefania Galimberti, Giorgio Bovo, Anna Vergani, Cristina Arosio, Raffaella Mariani, Alessandro Redaelli, et al. "Iron Accumulation in Chronic Hepatitis C." American Journal of Clinical Pathology 124, no. 6 (December 2005): 846–53. http://dx.doi.org/10.1309/x4uh5q68q4j3gdnv.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Nozic, Darko, Bela Balint, Nebojsa Stankovic, Jovan Dimitrijevic, and Gorana Neskovic. "Significance of iron reduction for the therapy of chronic hepatitis C." Vojnosanitetski pregled 62, no. 2 (2005): 161–64. http://dx.doi.org/10.2298/vsp0502161n.

Full text

Abstract:

Background. It has been established that many patients with chronic hepatitis C have elevated serum iron, feritin levels and iron deposits in the liver. Therefore, the liver damage due to hepatitis C virus may be aggravated with iron overload. In many studies higher levels of iron in the blood and the liver were connected with the decreased response to interferon-alfa therapy for chronic viral hepatitis C. Recent introduction of pegylated interferons plus ribavirin has improved the therapeutic response, so it is now possible to cure more than 50% of the patients. Case report. Three patients with chronic hepatitis C and iron overload were presented. Iron reduction therapy using phlebotomy or eritrocytapheresis with plasmapheresis was done at different times in regard to specific antiviral therapy or as a sole therapy. Conclusion. It has been shown that iron reduction, sole or combined with antiviral therapy, led to the deacreased aminotransferase serum activity and might have slow down the evolution of chronic hepatitis C viral infection.

APA, Harvard, Vancouver, ISO, and other styles

4

Fujita, Naoki, and Yoshiyuki Takei. "Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C." Journal of Gastroenterology 42, no. 11 (November 22, 2007): 923–26. http://dx.doi.org/10.1007/s00535-007-2110-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Price, Leslie, and Kris V. Kowdley. "The Role of Iron in the Pathophysiology and Treatment of Chronic Hepatitis C." Canadian Journal of Gastroenterology 23, no. 12 (2009): 822–28. http://dx.doi.org/10.1155/2009/290383.

Full text

Abstract:

Increased hepatic iron content may be observed in patients with chronic hepatitis C infection, and may contribute to disease severity. The presence of hemochromatosis gene mutations is associated with increased hepatic iron accumulation and may lead to accelerated disease progression. Hepatic iron depletion has been postulated to decrease the risk of hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. It is possible that iron depletion stabilizes or improves liver histology and slows disease progression in these individuals. The present article reviews the prevalence and risk factors for hepatic iron overload in chronic hepatitis C, with emphasis on the available data regarding the efficacy of iron depletion in the treatment of this common liver disease.

APA, Harvard, Vancouver, ISO, and other styles

6

Ivashkin, V. T., E. Lukina, M. Majevskaja, A. Levina, E. Sysojeva, C. Pavlov, N. D. Khoroshko, and G. A. Frank. "Iron status of patients with chronic hepatitis C." Journal of Hepatology 28 (1998): 205. http://dx.doi.org/10.1016/s0168-8278(98)80996-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

BURT, MICHAEL J., and W. GRAHAM COOKSLEY. "The inﬂuence of iron on chronic hepatitis C." Journal of Gastroenterology and Hepatology 13, no. 3 (March 1998): 330–33. http://dx.doi.org/10.1111/j.1440-1746.1998.01549.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Indrasari, Nuri Dyah, Ina Susianti Timan, and Pustika Amalia. "PERBEDAAN KOLAGEN IV DI KERUSAKAN HATI DAN INFEKSI HEPATITIS C PASIEN TALASEMIA DENGAN KELEBIHAN ZAT BESI (Diferrence of Collagen IV in Liver Damage and Hepatitis C Infection in Iron Overload Thalassemia Patients)." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 22, no. 1 (April 14, 2018): 1. http://dx.doi.org/10.24293/ijcpml.v22i1.1214.

Full text

Abstract:

Thalassemia patients who receive repeated blood transfusions are at risk of iron overload and hepatitis C infection. Iron overload cancause iron deposit in many organs, including the liver. Iron deposits in the liver and hepatitis C infection can cause chronic inflammationof the liver and induce hepatic stellate cells to produce Extra Cellular Matrix (ECM) causing liver fibrosis. Laboratory diagnosis of liverfibrosis is based on direct and indirect markers. Collagen IV is a direct marker reflecting ECM degradation in liver fibrosis. AlanineTransaminase (ALT), Aspartate Transaminase (AST) and AST/ALT ratio are indirect markers reflecting liver cell damage due to liverfibrosis. The aim of this study was to investigate the difference of Collagen IV in liver damage and hepatitis C infection in thalassemiapatients with iron overload. Collagen IV was measured using ELISA, while ALT and AST were measured by enzymatic colorimetric assay.Fifty eight thalassemia patients with iron overload, 29 with hepatitis C and 29 without hepatitis C were studied. This study showed nosignificant difference in Collagen IV level, ALT, AST activity and AST/ALT ratio between subjects with and without hepatitis C(p 0.131,0.243, 0.256 and 0.726) and no significant correlation was found between collagen IV level and ALT activity, and between collagen IVand AST/ALT ratio (p 0.160 and 0.509). These findings indicate that Collagen IV showed no correlation with liver damage and hepatitisC infection in thalassemia patients with iron overload.

APA, Harvard, Vancouver, ISO, and other styles

9

Dostalikova-Cimburova, Marketa, Karolina Kratka, Jaroslav Stransky, Ivana Putova, Blanka Cieslarova, and Jiri Horak. "Iron Overload andHFEGene Mutations in Czech Patients with Chronic Liver Diseases." Disease Markers 32, no. 1 (2012): 65–72. http://dx.doi.org/10.1155/2012/790464.

Full text

Abstract:

The aim of the study was to identify the prevalence ofHFEgene mutations in Czech patients with chronic liver diseases and the influence of the mutations on iron status. The presence ofHFEgene mutations (C282Y, H63D, and S65C) analyzed by the PCR-RFLP method, presence of cirrhosis, and serum iron indices were compared among 454 patients with different chronic liver diseases (51 with chronic hepatitis B, 122 with chronic hepatitis C, 218 with alcoholic liver disease, and 63 patients with hemochromatosis). Chronic liver diseases patients other than hemochromatics did not have an increased frequency ofHFEgene mutations compared to controls. Although 33.3% of patients with hepatitis B, 43% of patients with hepatitis C, and 73.2% of patients with alcoholic liver disease had elevated transferrin saturation or serum ferritin levels, the presence ofHFEgene mutations was not significantly associated with iron overload in these patients. Additionally, patients with cirrhosis did not have frequencies ofHFEmutations different from those without cirrhosis. This study emphasizes the importance, not only of C282Y, but also of the H63D homozygous genetic constellation in Czech hemochromatosis patients. Our findings show that increased iron indices are common in chronic liver diseases butHFEmutations do not play an important role in the pathogenesis of chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease.

APA, Harvard, Vancouver, ISO, and other styles

10

MATSUMOTO, Masafumi, Shigeyoshi IMAMURA, Hitomi SATO, Masahiko TAKAMASU, Takeshi OKANOUE, and Kei KASHIMA. "Dietary iron reduction on patients with chronic hepatitis C." Kanzo 40, no. 8 (1999): 436–44. http://dx.doi.org/10.2957/kanzo.40.436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Iron in chronic hepatitis C"

1

HAYASHI, HISAO, TOSHIKUNI TAKlKAWA, KATSUMI KATO, SATOSHI TAKIYA, TSUNEAKI TAGAYA, JUNSUKE KURIKI, MOTOHIRO ARAO, and SHOSHI KATO. "BIOCHEMICAL IMPROVEMENT OF CHRONIC HEPATITIS C AFTER GASTROINTESTINAL BLEEDING." Nagoya University School of Medicine, 1994. http://hdl.handle.net/2237/16077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

NAOE, TOMOKI, HISAO HAYASHI, HIDEAKI MAEDA, HARUHIKO OHASHI, AKIHIRO TOMITA, and HIROSHI SAITO. "DETERMINATION OF FERRITIN AND HEMOSIDERIN IRON IN PATIENTS WITH NORMAL IRON STORES AND IRON OVERLOAD BY SERUM FERRITIN KINETICS." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shiono, Yuhta, Hisao Hayashi, Shinnya Wakusawa, Fujiko Sanae, Toshikuni Takikawa, Motoyoshi Yano, Kenntaro Yoshioka, and Hiros Saito. "Body iron stores and Iron restoration rate in Japanese patients with chronic Hepatitis C as measured during therapeutic Iron removal revealed neither Increased body iron stores nor effects of C282y and H63d mutations on iron indices." Nagoya University School of Medicine, 2001. http://hdl.handle.net/2237/5367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Naoe, Tomoki, Hideaki Maeda, Haruhiko Ohashi, Akihiro Tomita, Hisao Hayashi, and Hiroshi Saito. "INCREASING AND DECREASING PHASES OF FERRITIN AND HEMOSIDERIN IRON DETERMINED BY SERUM FERRITIN KINETICS." Nagoya University School of Medicine, 2013. http://hdl.handle.net/2237/18470.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lim, Teegan Reina. "Metabolic effects of hypoxia and chronic hepatitis C." Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8535/.

Full text

Abstract:

Hypoxia has been linked to the pathogenesis of hepatic steatosis in murine and human models. There is an abundance of data suggesting that HIFs play a central role in regulating hepatic lipid metabolism. This study suggested that hypoxia-induced hepatic lipid accumulation is through de novo lipogenesis and free fatty acid uptake, and is dependent on hypoxia inducible factors la and 2a. On the contrary, hepatitis C infection reduced de novo lipogenesis and free fatty acid uptake in both normoxic and hypoxic conditions in vitro, and this inhibition is viral strain-dependent. In the clinical setting, chronic hepatitis C {CHC) and non-alcoholic fatty liver diseases {NAFLD) are associated with hepatic steatosis and insulin resistance. Using an integrative physiological approach that measures lipid and carbohydrate flux in vivo we demonstrated that patients with CHC had modest increase in insulin resistance and that the relative contribution of tissue specific insulin sensitivity in patients with CHC and NASH varied. Furthermore, curing HCV infection improved hepatic and subcutaneous adipose tissue insulin resistance. The improvement in hepatic and adipose tissue insulin resistance was more pronounced in patients infected with genotype 3 HCV, whilst the improvement in skeletal muscle insulin resistance was more evident in genotype 1 infection, demonstrating a genotype-specific effect in the metabolic perturbation in CHC. Further studies are required to confirm that genotype specific effect of HCV on insulin resistance and its link with NASH.

APA, Harvard, Vancouver, ISO, and other styles

6

Christie, John Michael Landale. "Viral persistence in hepatitis C virus infection." Thesis, University of Southampton, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268465.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Verbaan, Hans. "Chronic hepatitis C infection with special reference to prevalence, aggravating factors and longterm outcome /." Lund : Gastroenterology and Hepatology Division, Dept. of Medicine, University Hospital, Lund University, 1997. http://books.google.com/books?id=SBdrAAAAMAAJ.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hui, Chee-kin, and 許志堅. "Chronic hepatitis C infection: diagnosis, fibrosis progression and interferon therapy." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B29756972.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Abbas, Amro M. "Pathogenesis of disease associated with chronic hepatitis C virus infection." Thesis, University of Nottingham, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Veldt, Bartholomeus Johannes. "Long-term clinical outcome of treatment for chronic hepatitis C." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/12624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Iron in chronic hepatitis C"

1

Ozaras, Resat, and Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shiffman, Mitchell L., ed. Chronic Hepatitis C Virus. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-1192-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

National Digestive Diseases Information Clearinghouse (U.S.). Chronic hepatitis C: Current disease management. Bethesda, MD]: National Digestive Diseases Information Clearinghouse, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Shih, Chiaho. Chronic hepatitis B and C: Basic science to clinical applications. New Jersey: World Scientific, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Foster, Graham. Management of Chronic Viral Hepatitis. London: Taylor & Francis Group Plc, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

D, Goldin R., ed. Management of chronic viral hepatitis. London: Martin Dunitz, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2009, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

San Francisco (Calif). Dept. of Public Health. Communicable Disease Control Unit. Chronic hepatitis B and hepatitis C infection surveillance report: 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Takahashi Memorial Forum (1995 Tokyo, Japan). Interferon therapy on chronic hepatitic C: Proceedings of the "Takahashi Memorial Forum", held in Tokyo, Japan on 25 November 1995. Edited by Takahashi Tadao 1908-, Yamanaka Masami, Okabe Kazuhiko, and Toda Gotaro. Amsterdam: Elsevier, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

San Francisco (Calif.). Dept. of Public Health. Communicable Disease Control Unit. Registry match: Chronic hepatitis B, hepatitis C infection and HIV : 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Iron in chronic hepatitis C"

1

Izumi, Namiki, Yasuhiro Asahina, Osamu Noguchi, Masakatsu Uchihara, Sukenobu Kawamura, Kaoru Tsuchiya, Kousei Hamano, Jun Itakura, Shozo Miyake, and Takahiro Sakai. "Hepatic Iron Accumulation and Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C." In HCV/Oxidative Stress and Liver Disease, 83–90. Tokyo: Springer Japan, 2003. http://dx.doi.org/10.1007/978-4-431-67005-6_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ide, Tatsuya, Fuyuhiko Akiyoshi, Michio Sata, Yasuyo Uchimura, Hiroshi Suzuki, and Kyuichi Tanikawa. "Hepatic Iron Staining in Chronic Hepatitis C Patients with Low HCV RNA Levels as a Predictive Marker for Interferon Therapy." In HCV/Oxidative Stress and Liver Disease, 76–82. Tokyo: Springer Japan, 2003. http://dx.doi.org/10.1007/978-4-431-67005-6_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Trabut, Jean Baptiste. "Chronic Hepatitis C." In Encyclopedia of Quality of Life and Well-Being Research, 899–900. Dordrecht: Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-007-0753-5_365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Athwal, Varinder, and Martin Prince. "Chronic Hepatitis C." In In Clinical Practice, 183–99. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43126-0_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cohen, Stanley Martin. "Chronic Hepatitis C." In Liver Disease, 75–87. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98506-0_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Arends, Joop E., Maria Cristina Leoni, and Dominique Salmon-Ceron. "Acute Hepatitis C." In Viral Hepatitis: Chronic Hepatitis C, 197–217. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Dieterich, Douglas, Marie-Louise Vachon, and Damaris Carriero. "Hepatitis C in Special Populations." In Chronic Viral Hepatitis, 97–134. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-565-7_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Forns, Xavier, and Jose M. Sánchez-Tapias. "Chronic viral hepatitis C." In Textbook of Clinical Gastroenterology and Hepatology, 610–17. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118321386.ch81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ozaras, Resat, and Hakan Leblebicioglu. "Global Epidemiology of Chronic Hepatitis C Virus Infection." In Viral Hepatitis: Chronic Hepatitis C, 1–24. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Karaca, Çetin. "Extrahepatic Manifestations of Hepatitis C Virus Infection." In Viral Hepatitis: Chronic Hepatitis C, 183–95. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Iron in chronic hepatitis C"

1

Prasetia Nurwidda, Arvi Dian, Poernomo Boedi Setiawan, Iswan Abbas Nusi, Herry Purbayu, Titong Sugihartono, Ummi Maimunah, Ulfa Kholili, et al. "Thrombocytopenia in Chronic Hepatitis C." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007340404460452.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kchir, H., D. KAFFEL, H. Dabbebi, D. ISSAOUI, H. Sahli, W. Hamdi, M. Elleuch, M. M. Kchir, R. Debbeche, and N. Maamouri. "AB1049 Rheumatological manifestations during chronic hepatitis c." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5886.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Nevkhoroshev, Yevhen, and Deonis Tkemaladze. "AUTOIMMUNE THYROIDITIS IN PATIENTS WITH CHRONIC HEPATITIS C." In TENDANCES SCIENTIFIQUES DE LA RECHERCHE FONDAMENTALE ET APPLIQUÉE, chair Lilia Bobro. European Scientific Platform, 2020. http://dx.doi.org/10.36074/30.10.2020.v2.07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"Secrum microRNA-122 with HCC in chronic hepatitis C." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

hela, KCHIR, Ons Gharbi, Dhilel Issaoui, Dhouha Cherif, Faten Limaiem, Mejda Essid, and Nadia Maamouri. "AB0529 SICCA SYNDROME DURING CHRONIC HEPATITIS C: PREVALENCE AND CHARACTERISTICS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Schlevogt, B., K. Böker, S. Mauss, H. Klinker, R. Heyne, R. Link, KG Simon, et al. "Weight gain after interferon-free clearance of chronic hepatitis C – Results from the German Hepatitis C-Registry (DHC-R)." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"3.0T 1H MRS in Assessing the Steatosis in Chronic Hepatitis C Patients." In 2018 International Conference on Medicine, Biology, Materials and Manufacturing. Francis Academic Press, 2018. http://dx.doi.org/10.25236/icmbmm.2018.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ruiz Gómez, A., L. Menéndez Naranjo, M. Sáez Garrido, A. Laorden Carrasco, M. Díaz Ramón, JÁ Cano Molina, and A. Espuny Miró. "5PSQ-033 Glecaprevir/pibrentasvir use in chronic hepatitis C: effectiveness and safety." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ionescu, R. A., L. M. Pana, V. M. Pompilian, A. Voicu, S. Caraiola, D. Ramba, C. R. Baicus, and A. Dan. "SAT0668 Articular involvement in chronic hepatitis c infection – a preliminary ultrasound study." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7464.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ma, Ling, YongSheng Yang, Xin Ge, YiDan Wan, and Xin Sang. "Prediction of disease progression of chronic hepatitis C based on XGBoost algorithm." In 2020 International Conference on Robots & Intelligent System (ICRIS). IEEE, 2020. http://dx.doi.org/10.1109/icris52159.2020.00151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Iron in chronic hepatitis C"

1

Kancheva, Lyudmila, Petar Nikolov, Tsvetelina Velikova, Ivan Valkov, Rossen Nikolov, and Lyudmila Mateva. Soluble CD14 is Associated with Disease Activity and Severity in Chronic Viral Hepatitis C and B. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, June 2018. http://dx.doi.org/10.7546/crabs.2018.06.17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Evon, Donna, Jipcy Amador, Paul Stewart, Bryce Reeve, Carol Golin, Anna Lok, Richard Sterling, et al. Changes in Health for Patients Who Complete Treatment for Chronic Hepatitis C Virus -- The PROP up TARGET Study. Patient-Centered Outcomes Research Institute® (PCORI), July 2020. http://dx.doi.org/10.25302/06.2020.cer.140820660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Xu, Yan, Yuyang Zhao, Yong Wang, Changyu Zhou, Xingang Wang, Yongqiang Dong, and Shaoyou Qin. Concurrent hepatic steatosis increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B or C virus infection: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!